Status:
RECRUITING
Gadoxetate Abbreviated MRI in Metastatic Colorectal Cancer
Lead Sponsor:
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Collaborating Sponsors:
Bayer
Conditions:
Liver Metastasis Colon Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
After a patient is diagnosed with colon cancer, they receive a CT of the chest, abdomen, and pelvis to see if the cancer has spread (metastasized) to other parts of the body. A common site for the can...
Detailed Description
BACKGROUND Colorectal cancer (CRC) is the third most commonly diagnosed cancer in Canada and the second leading cause of death in both men, and women (1). In 2021, 24800 Canadians were diagnosed with...
Eligibility Criteria
Inclusion
- Male or female, 18 years of age or older
- Diagnosis of colorectal cancer, biopsy proven
- Prior imaging showing liver lesions that may be metastases
- Provision of signed and dated informed consent form
- Willingness to comply with study procedures and availability for the duration of the study
- Able to tolerate MRI required by protocol
Exclusion
- Presence of implanted medical device or metallic object that is MR incompatible
- Baseline eGFR of \< 30 mL/min/1.73 m2
- Severe claustrophobia not relieved by oral anxiolytics
- Documented severe allergic-like reaction gadolinium-based contrast agent
- Weight greater than allowable on MRI table
- Pregnancy
- Diffuse liver metastases, i.e. definitively unresectable
- Severe liver dysfunction, ALBI grade 3
Key Trial Info
Start Date :
July 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2027
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT05314400
Start Date
July 1 2022
End Date
October 1 2027
Last Update
July 11 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Joseph's Healthcare
London, Ontario, Canada, N6A 4V2
2
London Health Sciences Centre
London, Ontario, Canada, N6A5A5